Peer-influenced content. Sources you trust. No registration required. This is HCN.

Northwestern MedicineEpigenetic ‘Priming’ Boosts Ovarian Cancer Immunotherapy

An epigenetic inhibitor can boost immune system activity in patients with ovarian cancer, according to a Northwestern Medicine study published in the Journal of Clinical Investigation.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form